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Background: Cyclophosphamide (CPA) can activate immunogenic tumor cell death, which induces immune-based
tumor ablation and long-term anti-tumor immunity in a syngeneic C57BL/6 (B6) mouse GL261 glioma model when
CPA is given on a 6-day repeating metronomic schedule (CPA/6d). In contrast, we find that two other syngeneic B6
mouse tumors, LLC lung carcinoma and B16F10 melanoma, do not exhibit these drug-induced immune responses
despite their intrinsic sensitivity to CPA cytotoxicity.
Methods: To elucidate underlying mechanisms, we investigated gene expression and molecular pathway changes
associated with the disparate immune responsiveness of these tumors to CPA/6d treatment.
Results: Global transcriptome analysis indicated substantial elevation of basal GL261 immune infiltration and strong
CPA/6d activation of GL261 immune stimulatory pathways and their upstream regulators, but without preferential
depletion of negative immune regulators compared to LLC and B16F10 tumors. In LLC tumors, where CPA/6d
treatment is shown to be anti-angiogenic, CPA/6d suppressed VEGFA target genes and down regulated cell
adhesion and leukocyte transendothelial migration genes. In GL261 tumors implanted in adaptive immune-deficient
scid mice, where CPA/6d-induced GL261 regression is incomplete and late tumor growth rebound can occur, T cell
receptor signaling and certain cytokine-cytokine receptor responses seen in B6 mice were deficient. Extending the
CPA treatment interval from 6 to 9 days (CPA/9d) −which results in a strong but transient natural killer cell
response followed by early tumor growth rebound − induced fewer cytokines and increased expression of drug
metabolism genes.
Conclusions: These findings elucidate molecular response pathways activated by intermittent metronomic CPA
treatment and identify deficiencies that characterize immune-unresponsive tumor models and drug schedules.
Keywords: Metronomic cyclophosphamide, Immune responsiveness, Cd8+ T cells, NK cells, RNA-seq, Upstream
regulator, Drug schedule* Correspondence: djw@bu.edu
Division of Cell and Molecular Biology, Department of Biology and
Bioinformatics Program, Boston University, 5 Cummington Mall, Boston, MA
02215, USA
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Wu et al. BMC Cancer  (2016) 16:623 Page 2 of 17Background
Certain cytotoxic anti-cancer drugs, including doxorubi-
cin, oxaliplatin, and cyclophosphamide (CPA), can activate
immunogenic tumor cell death, triggering robust anti-
tumor immune responses [1, 2]. Hallmarks of immuno-
genic cell death [1, 3] include exposure of calreticulin on
the tumor cell surface, which serves as an “eat-me” signal
for dendritic cells [4] and macrophages [5], and HSP90 ex-
posure, which facilitates dendritic cell-tumor cell adhesion
and stimulates dendritic cell maturation [6]. Release of the
alarmin molecule HMGB1 into the extracellular matrix
activates toll-like receptors and stimulates dendritic cell
antigen presentation and IL1β production, leading to CD8
T cell activation [7, 8], while ATP released from apoptotic
tumor cells can activate dendritic cells [9]. Less well de-
fined are the downstream anti-tumor immune responses
induced by these initial immunogenic cell death events, as
well as the factors that determine whether a cytotoxic
drug intrinsically capable of eliciting immunogenic cell
death will actually do so, and in a way that induces a
strong anti-tumor immune response.
CPA is a bifunctional alkylating agent widely used for
cancer treatment [10]. CPA can induce immunogenic
tumor cell death and activate robust immune responses in
several tumor models [11–13]. In gliomas, CPA induces
major tumor regression and activates robust anti-tumor
immune responses when given on a metronomic schedule
[14, 15] that is intermittent, involving repeated dosing
every 6 days (CPA/6d), as seen in both scid (adaptive
immune-deficient) mice and in fully immune competent
C57BL/6 (B6) mice [16–20]. Glioma regression achieved
in scid mice may be followed by late tumor growth re-
bound [17, 18], whereas regression is sustained in a fully
immune competent, syngeneic B6 mouse model and leads
to long-term tumor-specific immunity [20]. Several inter-
ferons were identified as major upstream regulators of the
immune responses in CPA/6d-treated U251 (human) and
9L (rat) gliomas implanted in scid mice [21]. Tumor-
associated gene responses identified in these xenograft
models include induction of many cytokines, chemokines,
and immune regulatory genes linked to innate immune
cell recruitment and tumor regression, as well as tumor
escape [21]. It is unclear, however, which pathways and
mechanisms dominate the response to CPA/6d treatment
in an immune competent mouse host. Also unknown is
whether strong anti-tumor immune responses are acti-
vated by the CPA/6d regimen in other, non-glioma models
that show strong intrinsic sensitivity to CPA cytotoxicity.
Here, we use global transcriptomic profiling by RNA-
seq to investigate the molecular signaling pathways asso-
ciated with the immune response of GL261 gliomas to
intermittent metronomic CPA treatment in a syngeneic,
immune competent B6 mouse host. The profile of gene
expression changes seen in GL261 gliomas, which showstrong immune responsiveness to CPA/6d treatment, is
compared to the changes seen in two other B6 mouse
syngeneic tumor models that are intrinsically sensitive to
CPA cytotoxicity, LLC Lewis lung carcinoma and B16F10
melanoma, but which, we show here, do not undergo
CPA-induced tumor regression or mount a strong anti-
tumor immune response. We also compare gene responses
induced by CPA/6d treatment of GL261 tumors implanted
in scid mice (GL261(scid)) to those induced in GL261 tu-
mors in the fully immune competent B6 mouse model
(GL261(B6)). Finally, we compare gene responses of CPA/
6d-treated GL261(scid) tumors to those induced when
CPA is given on a 9-day repeating metronomic schedule
(CPA/9d), where tumor-infiltrating natural killer (NK) cell
and other innate immune responses are initially very strong
but are not sustained, and where early resumption of robust
tumor growth occurs, despite continued CPA treatment
[18]. Molecular pathways associated with tumor respon-
siveness to metronomic CPA treatment are identified along
with upstream regulators (UPRs) predicted by Ingenuity
Pathway Analysis (IPA). Our findings give new insights into
the genes and pathways that characterize the wide range of
immune responsiveness to anti-cancer drug treatment seen
in different tumor models and help elucidate the impact of
drug scheduling and the adaptive immune system on tumor
responses to immunogenic metronomic chemotherapy.
Methods
Tumor cell lines, mouse tumors, and treatments
Mouse tumor cell lines syngeneic in B6 mice were authen-
ticated by and obtained from Developmental Therapeutics
Program Tumor Repository (National Cancer Institute,
Frederick, MD) (GL261 glioma) and ATCC (Manassas,
VA) (LLC Lewis lung carcinoma (ATCC® CRL-1642™) and
B16F10 melanoma (ATCC® CRL-6475™)). RNA-seq ana-
lysis (below) of the X-chromosome gene Xist and the Y-
chromosome genes Ddx3y and Eif2s3y indicated that
GL261 and B16F10 tumor cells are male, and LLC tumor
cells are female. Cells were grown at 37 °C in a humidified
5 % CO2 atmosphere in RPMI-1640 culture medium con-
taining 10 % fetal bovine serum, 100 units/ml penicillin
and 100 μg/ml streptomycin. Tumor cells were assayed
for their intrinsic sensitivity to activated CPA using 4-
hydroperoxy-CPA in a 4-day growth inhibition assay
[22]. Six-week-old (20–23 g) male B6 mice and 6-week-
old (26–28 g) male ICR/Fox Chase immune deficient scid
mice (Taconic Farms, Germantown, NY) were housed and
treated using protocols specifically reviewed for ethics and
approved by the Boston University Institutional Animal
Care and Use Committee. GL261 glioma cells (4 × 106)
were implanted by s.c. injection on the posterior flanks of
B6 mice (GL261(B6) model) [20] or scid mice
(GL261(scid) model) [18] in 0.2 ml serum-free RPMI per
site using a U-100 insulin syringe and a 28.5 gauge needle
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(1 × 106) or LLC Lewis lung carcinoma cells (2 × 106)
were implanted by s.c. injection on the posterior flanks of
B6 mice in the same manner. Tumor areas (length ×
width) were measured twice weekly using Vernier calipers
(VWR International, Cat.# 62379-531) and tumor vol-
umes were calculated: Vol = (π/6)*(L*W)3/2. Tumor vol-
umes (~500–750 mm3, mean values) were normalized to
a value of 100 % on the first day of CPA treatment (t =
0 days) to control for differences in initial tumor size. This
enabled us to reach statistical significance with fewer mice
[20], in accordance with our Institutional Animal Care
and Use Committee guidelines. Mouse body weights were
measured at least twice a week and normalized in the
same manner. Tumor-bearing mice were treated every
6 days with CPA at 140 mg/kg-body weight (CPA/6d) [16,
17]. CPA was administered as a monohydrate (Cat. #
C0768, Sigma-Aldrich, St. Louis, MO) dissolved in sterile
PBS, with the CPA doses reported here based on the non-
hydrated molecular weight of 261. Where indicated, mice
bearing GL261(scid) tumors were treated with same dose
of CPA, but given on a 9 day repeating schedule (CPA/
9d). In all cases, qPCR and RNA-seq analysis were carried
out using tumor tissue from untreated mice (control
group) and from CPA-treated mice collected 6 days after
the last CPA treatment. Thus, we monitored gene expres-
sion at a consistent point in time for all tumor samples,
including CPA/6d-treated vs. CPA/9d-treated GL261 tu-
mors. Additional file 1: Table S1 shows the number of
mice included in each treatment group.
Tumor blood vessel immunostaining
Cryosections prepared from LLC tumors were mounted
on slides and immunostained with antibody to mouse
CD31 (BD Pharmingen, Cat.# 557355, 1:1000 dilution)
to visualize tumor blood vessels. Cyosections were hy-
drated in 1x PBS, fixed in 3.2 % paraformaldehyde for
15 min, permeabilized with 1 % Triton X-100 on ice
for 5 min, treated with 3 % H2O2 for 5 min, and blocked
for 20 min in 4 % normal rabbit serum in PBS (blocking
solution) containing avidin (Vector Labs, avidin/biotin
blocking kit, Cat.# SP-2001) at 4 drops/ml. Slides were in-
cubated for 1 h at room temperature with anti-CD31 anti-
body (1:1000 dilution in blocking solution containing
biotin (Vector Labs) at 4 drops/ml), followed by 1 h incu-
bation at room temperature with biotinylated rabbit anti-
rat secondary antibody (Vector labs, Cat.# 4000, 1:200
dilution in blocking solution), followed by Vectastain ABC
reagent (Vector labs, Cat.# PK4000) for 30 min, and VIP
(Vector labs, Cat. # SK-4600) color development for 40 s.
Each step, above, was followed by a PBS wash. Color de-
velopment was terminated by two 5 min washes in dis-
tilled water, followed by a 5 min rinse in tap water. Slides
were dehydrated in 95 % ethanol for 2 min twice, followedby 100 % ethanol for 2 min twice, xylene for 3 min twice,
and Vectamount mounting (Vector Labs, Cat.# H-5000).
Slides were dried overnight in a fume hood and imaged
with an Olympus FSX100 microscope at 4.2x magnifica-
tion. Images were converted to gray scale for quantifica-
tion using NIH image J software (http://imagej.nih.gov/ij/).
Gene expression analysis by qPCR and RNA-seq
Extraction of total RNA from individual tumors using
Trizol reagent, and qPCR analysis of relative RNA levels
for immune cell marker genes were performed as de-
scribed [16]. Tumor RNA samples having Agilent Bioa-
nalyzer RIN values > 7 were grouped into two separate
pools (biological replicates) for each treatment group
and used for RNA-seq library preparation and high
throughput sequencing, as detailed in the legend to
Additional file 1: Table S1. For GL261 tumors implanted
in scid mice, RNA-seq libraries were prepared using the
Illumina TruSeq® mRNA library Prep kit (Cat# RS-122-
2101). RNA-seq libraries were prepared from all other
tumor RNA samples using NebNext® Ultra Directional
RNA Library Prep kit for Illumina® (New England Bio-
labs, Ipswich, MA; Cat# E7420). NEBNext® Multiplex
Oligos for Illumina® (New England Biolabs, Cat# E7335S)
were used for sample multiplexing. Agencourt AMPure
XP beads (Beckman Coulter, Cat# A63880) were used for
size selection and purification. Library quality and insert
size distribution were assessed using the Agilent Bioanaly-
zer DNA high sensitivity chip kit (Agilent Technologies,
Cat# 5067-4627). Samples were subject to Illumina se-
quencing using a HiSeq instrument generating either 50
or 68 nt single-end reads. All raw and processed sequen-
cing data are available under accession number GSE71491
at GEO (http://www.ncbi.nlm.nih.gov/geo/); further de-
tails are shown in Additional file 1: Table S1 legend. Se-
quence reads were demultiplexed and then aligned to the
mouse genome (build mm9; NCBI 37) using Tophat (ver-
sion 2.0.13) [23, 24]. Differential expression analysis for
RefSeq genes was conducted using the Bioconductor
package DESeq (version 1.18.0) [25]. CPA-induced gene
responses meeting the cutoff values of |fold-change|
(FC) > 2 and p < 0.001 for each tumor model and treatment
condition are shown in Additional file 1: Table S1A-F and
summarized in Additional file 2: Figure S1.
Upstream regulator analysis
A combined list of genes that were either up regulated or
down regulated by CPA treatment at |FC| > 2 and p < 0.001
was uploaded together with the corresponding gene ex-
pression FC values for Ingenuity Pathway Analysis (IPA)
(www.ingenuity.com/products/ipa). The Upstream Analysis
module of IPA was used to identify upstream regulators
(UPRs), their predicted activation Z-scores and bias-
corrected Z-scores, targeted molecules in each dataset,
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regulated genes in the IPA database, and the associated
mechanistic networks. Individual UPRs were identified as
being “Activated” or “Inhibited” as predicted by IPA. Since
our goal was to identify endogenous master UPRs induced
by metronomic CPA treatment, we excluded all UPRs that
are classified by IPA as chemicals, except endogenous
mammalian chemicals. We also excluded group UPRs that
duplicate individual constituent UPRs. When two UPRs
with same name were identified, e.g., one from mouse an-
other from human, the UPR with higher activation score
was retained. The resultant full UPR lists are shown in
Additional file 3: Table S2A-E. Overall results obtained
using UPR analysis are summarized in Additional file 2:
Figure S2.
To increase the stringency of UPR identification, UPRs
identified by IPA using IPA’s default conditions were fil-
tered by applying the following conditions: p-value of
overlap < 0.0001, number of targeted genes > 10, and ab-
solute values of the predicted activation Z-score and
bias-corrected activation Z-score both > 2 (stringent
UPRs; Additional file 2: Figure S3). The following criteria
were applied to assess the uniqueness of each stringent
UPR to a given tumor model, as outlined in Additional
file 2: Figure S4. A stringent UPR identified in tumor
model A was designated unique to tumor model A, as
compared to tumor model B, if it met either of the fol-
lowing two conditions: (1) the UPR was absent from the
listing of UPRs generated by IPA under default condi-
tions for tumor model B; (2) |activation Z-score| and
|bias-corrected Z-score| for the UPR are both > 2 in
tumor model B, but show the opposite activation state,
i.e., Activated in one tumor model vs. Inhibited in the
other tumor model. UPRs that met either of the follow-
ing two criteria were considered as candidate unique
UPRs for tumor model A: (1) |activation Z-score| and
|bias-corrected Z-score| for the UPR are both < 2 in
tumor model B; or (2) either |activation Z-score| or
|bias-corrected Z-score| for the UPR in tumor model B,
but not both, is > 2, and is in the opposite direction as
for the UPR in tumor model A. The p-value of overlap
was then used to determine the uniqueness of each can-
didate unique UPR, following the last three decision tree
steps in Additional file 2: Figure S4. Thus, if the p-value
of overlap for a given candidate UPR was ≥ 0.001 in
tumor model B, the UPR was designated unique to
tumor model A. Alternatively, if the p-value of overlap
of the candidate UPR in tumor model B was < 0.001
but ≥ 0.0001, and if it was > 100-fold higher than the p-
value for overlap of that UPR in tumor model A, then
the UPR was designated unique to tumor model A.
However, if the p-value of overlap of a given candidate
UPR was < 0.0001 in tumor model B, the UPR was not
considered unique to tumor model A, despite its havingan |activation Z-score| or a |bias-corrected Z-score| < 2
in tumor model B, and even if its p-value of overlap
was > 100-fold higher than that of the UPR in the model
A (Additional file 2: Figure S4).
The numbers of stringent UPRs identified in each
tumor model (Additional file 4: Table S3A-E) and each
tumor model comparison (which identify either com-
mon or unique UPRs for each model; Additional file 4:
Table S3F-K) are summarized in Additional file 2: Figure S2.
To identify CPA-induced UPRs unique to GL261(scid) tu-
mors as compared to GL261(B6) tumors, we compared
the full set of UPRs associated with CPA-induced gene re-
sponses in GL261(B6) tumors (Additional file 3: Table S2A)
to the set of 179 stringent UPRs common to the responses
of GL261(scid) tumors to CPA/6d and CPA/9d treatment
(Additional file 4: Table S3F), as outlined in Additional
file 2: Figure S2 (right). This approach was based on the
high overall similarity of gene responses (77 % simi-
larity, Additional file 1: Table S1F) and stringent
UPRs (Additional file 4: Table S3F vs. Additional file 4:
Tables S3D-E) between the CPA/6d and CPA/9d treat-
ments, both of which effected strong tumor regression
when the tumors were collected 6 days after the second
CPA injection. When assessing the uniqueness of the
stringent UPRs identified in the GL261(B6) tumor model
(Additional file 4: Table S3A) as compared to the
GL261(scid) model, we considered the full set of UPRs de-
rived from CPA/6d-treated GL261(scid) tumors (Additional
file 3: Table S2D; see Additional file 2: Figure S2).
KEGG pathway analysis
Genes that were up or down regulated significantly by
CPA treatment at |(FC)| > 2 and p < 0.001 were input as
separate gene lists for analysis using DAVID Bioinfor-
matics Resources 6.7 with default parameters (http://
david.abcc.ncifcrf.gov/tools.jsp) to identify KEGG path-
ways, as well as DAVID functional annotation clusters
(DAVID clusters) enriched in each set of CPA-regulated
genes. KEGG pathways with p-values < 0.05 and DAVID
clusters with enrichment score > 1.3 were deemed sig-
nificant (Additional file 5: Table S4). KEGG pathways
specific to one tumor model or treatment condition
were identified from the sets of genes that showed a sig-
nificant response to CPA in a given direction (e.g., up
regulation) in tumor model or treatment condition A
but not in tumor model/treatment condition B, as fol-
lows. Genes that showed significant up regulation by
CPA at |FC| > 2 and p < 0.001 in tumor model A and sig-
nificant down regulation in tumor model B were consid-
ered specific response genes for both A and B. Other
tumor model A-specific response genes were those
showing at least a 2-fold greater response in tumor
model A than tumor model B, as follows. We first iden-
tified all genes showing a significant response to CPA
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and then removed all genes for which 0.5 ≤ expression
ratio-Tumor model A/expression ratio-Tumor model
B ≤ 2. The combined set of all tumor model A-specific
up regulated genes (and similarly for down regulated
genes) was then used to identify KEGG pathways spe-
cific to tumor model A, as compared to tumor model B,
as outlined in Additional file 2: Figure S5 and S6.
When comparing KEGG pathways activated by the
CPA/6d and CPA/9d schedules, where a limited number
of tumor model-specific genes were identified, we re-
laxed the threshold for a difference in expression ratios
between tumor models from >2-fold to >1.33-fold when
inputting genes for pathway analysis. In an alternative
approach, we reduced the significance filter for genes
under consideration to |FC| > 1.5 and p < 0.001, as speci-
fied in the text. When comparing KEGG pathways acti-
vated in GL261(scid) vs. GL261(B6) tumors, we increased
the robustness of the analysis by considering those
GL261(scid) genes showing a significant response to both
CPA/6d and CPA/9d (Additional file 1: Table S1F).
Immunosuppressive factors
A list of 124 immunosuppressive genes was compiled
from the Gene Ontology term “Negative regulation of
immune response” (GO:0050777), which included 196
human and 153 mouse genes. Human gene symbol were
converted to mouse gene symbols using MammalHom
(http://depts.washington.edu/l2l/mammalhom.html) or by
manually checking the NCBI Gene database (http://
www.ncbi.nlm.nih.gov/gene/) where no mouse genes were
identified by MammalHom. Genes redundant between
human and mouse, and isoforms within a given species
were removed. The resultant list of 124 negative regula-
tors of immune response (Additional file 6: Table S5A)
was used to identify immune suppressive factors that may
contribute to the differential CPA responsiveness between
tumor models, as well as differences in response between
B6 and scid mouse host, and between the CPA/6d and
CPA/9d schedules.
Results
Metronomic CPA does not activate robust immune cell
recruitment or induce tumor regression in LLC and
B16F10 tumors
Metronomic CPA treatment on a 6-day repeating sched-
ule (CPA/6d) induces a complete, immune cell-dependent
regression of GL261 tumors implanted in immune com-
petent C57BL/6 mice (GL261(B6) tumor model) and acti-
vates long-term tumor-specific immunity [20]. We
investigated two other B6 syngeneic tumor cell lines, LLC
Lewis lung carcinoma and B16F10 melanoma, both of
which are intrinsically sensitive to the cytotoxic effects of
4-hydroxy-CPA, the activated form of CPA (Fig. 1a). Incontrast to GL261 tumors [20], LLC and B16F10 tumors
showed only minor (LLC) or moderate (B16F10) tumor
growth delay in response to metronomic CPA treatment
(Fig. 1b). Differences in tumor growth rate do not account
for the differences of CPA/6d-induced growth inhibition
of LLC and B16F10 tumors compared to each other and
compared to GL261 tumors (data not shown). Rather,
analysis of marker genes for macrophages (CD68) and
cytotoxic effectors of natural killer and T cells (perforin1,
granzyme B) indicated that metronomic CPA induced
weak (B16F10) or no increases (LCC) in immune cell
marker genes (Fig. 1c), in contrast to the strong increases
in all three immune markers following CPA/6d treatment
of GL261 tumors in the same B6 mouse model [20]. LLC
and B16F10 tumors were therefore designated metro-
nomic CPA immune unresponsive (Table 1).
Gene expression changes and their upstream regulators
(UPRs) in responsive vs. unresponsive tumor models
Global transcriptional profiling by RNA-seq was used to
further characterize immune-based gene responses in
metronomic CPA-treated GL261(B6) tumors and to elu-
cidate the extent of immune unresponsiveness of LLC
and B16F10 tumors and its underlying mechanisms. We
identified 2119 up regulated genes and 809 down regu-
lated genes in CPA/6d-treated GL261(B6) tumors (sig-
nificance cutoff values |FC| > 2 and p < 0.001; Table 1,
Additional file 1: Table S1A). Many fewer genes (663 up
regulated, 394 down regulated genes) responded to CPA
in B16F10 tumors, and even fewer gene responses were
seen in LLC tumors (151 up regulated, 70 down regu-
lated genes; Table 1, Additional file 1: Table S1B-C),
which are the most intrinsically sensitive to activated
CPA but showed the weakest anti-tumor and immune
responses (Fig. 1). Analysis of the regulated gene sets in
each tumor model identified upstream regulators (UPRs),
which were predicted to be either activated or inhibited by
metronomic CPA based on the direction of response of
their downstream target genes. The full sets of UPRs asso-
ciated with the CPA-responsive genes in each tumor
model (Additional file 3: Table S2A-C) were used to iden-
tify top UPRs (Table 1, stringent UPRs; Additional file 4:
Table S3A-C) by applying more stringent selection criteria
(Additional file 2: Figures S2, S3, S4). Stringent UPRs that
were uniquely associated with a given tumor model or
that were common between tumors models were also
identified.
47 out of 180 stringent UPRs associated with GL261(B6)
tumor responses to CPA were unique to GL261(B6) tu-
mors as compared to both unresponsive tumor models
(Additional file 4: Table S3G). These 47 UPRs encompass
four categories (Table 2): 1) Factors that facilitate tumor
regression by immune-mediated mechanisms (23 activated
UPRs that activate immune responses, including HMGB1,
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Fig. 1 Intrinsic sensitivity to activated CPA, anti-tumor activity, and immune cell recruitment/activation in metronomic CPA-treated B16-F10 and
LLC tumors. a, Sensitivity of LLC and B16F10 tumor cell lines to 4-hydroperoxy-CPA in cell culture, determined using a 4-day growth inhibition
assay. EC50, effective concentration for 50 % growth inhibition. EC50 for 4-hydroperoxy-CPA-treated GL261 cells, 0.15 μM (data not shown). b, In
vivo tumor growth profiles for LLC and B16F10 tumors in response to treatment with 140 mg/kg CPA on treatment days 0, 6, and 12 (arrows
along X-axis). c, qPCR analysis of the indicated immune markers in CPA-treated and untreated LLC and B16F10 tumors (shown in b) implanted
s.c. in B6 mice. Data in a is representative of n = 5 culture wells per data point, data in b is based on mean ± SE for n = 10–14 tumors per group,
and data in c based on n = 4–5 tumors per group. *, p < 0.05 by two-tailed t-test
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ited UPRs that inhibit immune responses), or by inhi-
biting tumor cell survival (6 inhibited UPRs that
promote tumor cell survival); 2) Factors that counter-
act tumor regression by inhibiting immune responses
(activated PTGS2 [27]) or by promoting cell survival
(activated UPRs FN1 [28] and FGFR2 [29]); 3) Factors
that are either positive or negative immune response
modulators, depending on the cell context (10 UPRs);
4) Glioma cell lineage-related factors (activated UPRs
SIM1 [30] and PAX7 [31]).VEGFA was identified as an activated UPR in CPA-
treated GL261(B6) tumors (Additional file 4: Table S3A),
consistent with the requirement for VEGFA signaling via
VEGFR2 for CPA/6d to induce immune cell recruitment
in responding gliomas [16, 19]. In contrast, VEGFA was
a uniquely inhibited UPR in CPA-treated LLC tumors
(Additional file 4: Table S3B), suggesting that CPA/6d
inhibits VEGFA-dependent angiogenesis in this tumor
model. VEGFA was not a significant UPR in B16F10
tumors. The predicted UPR activity of VEGFA in LLC
tumors was verified experimentally by the significant
Table 1 Tumor models, mouse hosts, CPA schedules, gene responses and UPR analysis. RNA-seq was performed on two replicated
RNA pools for each condition (Additional file 1: Table S1 legend)
Responsive tumors Unresponsive tumors
Tumor GL261 LLC B16F10
Mouse host B6 scid scid scid B6 B6
CPA schedule (days) 6 6 9 6 and 9a 6 6










Up regulated genes 2119 2574 2713 2352 151 663
Down regulated genes 809 1250 1564 1176 70 394
Stringent Upstream Regulators (UPRs) 180 210 218 179 6 93
Shown here is a summary of tumor responses to drug treatment, for GL261(B6) [20], GL261(scid) [18], LLC and B16F10 tumors (Fig. 1), the number of genes up or
down regulated at |FC| > 2 and p < 0.001 (Additional file 1: Table S1), and the number of significant UPRs (Additional file 4: Table S3) after filtering of the full set of
UPRs output by IPA (Additional file 3: Table S2)
a, Number of commonly regulated genes and UPRs responding in common between GL261(scid) tumors treated with CPA/6d and GL261(scid) tumors treated
with CPA/9d
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CPA/6d treatment (Fig. 2). We also identified six UPRs
unique to CPA-treated B16F10 tumors vs. GL261(B6)
tumors that promote tumor cell survival or tissue repair
and may contribute to B16F10 tumor unresponsiveness:
activated UPRs KDM5B [32], RBL2 [33] and SPARC
[34–36]; and inhibited UPRs FOXM1 [37], CD24 [38,
39] and CSF2 [40]) (Additional file 4: Table S3C). CSF2,
which stimulates intra-tumoral dendritic cell expansion
and induces significant CD4+ and CD8+ T cell anti-
tumor immune responses [41, 42] was the top uniquely
activated UPR (most significant UPR, based on p-value
of overlap) in CPA-treated GL261 tumors (Table 2,
Additional file 4: Table S3G).
59 stringent UPRs were common to GL261(B6) and
B16F10 tumors (Additional file 4: Table S3H). Of these,
the top (most significant) UPRs include IFNB1, IFNG,
IL1B, IL6, TGFB1, TNF and TP53, which are activated
UPRs, and MYC, which is inhibited. IFNB1, IFNG and IL6
were also identified as highly significant activated UPRs in
studies of CPA/6d-treated U251 and 9L tumors in scid
mice [21]. However, the fact that these same UPRs are also
activated in the CPA/6d immune unresponsive B16F10 tu-
mors indicates that activation of these UPRs alone is insuf-
ficient to induce a robust downstream anti-tumor immune
response. Three top GL261(B6) and B16F10 common
UPRs have a more significant p-value of overlap in B16F10
tumors than in GL261(B6) tumors (activated UPRs
CDKN2A and IRF7; inhibited UPR TBX2; Additional file
4: Table S3H), suggesting they might contribute to the re-
duced responsiveness of B16F10 tumors. The activation of
three stringent UPRs related to DNA damage pathways
[43–45] in both GL261 and LLC tumors (CHUK/
IKBKA, IKBKB and JUN) or in all three tumor
models (CHUK, IKBKB) (Additional file 4: Table S3A-
C) may reflect the cytotoxic responses common to CPA
treatment in all three tumor models.KEGG pathways activated in responsive and unresponsive
tumor models
Immune response-related pathways were most highly
enriched in the 2119 genes up regulated by CPA/6d in
GL261(B6) tumors. The top 24 pathways (p < 0.0001)
can be classified into three groups (Table 3A; full path-
way listing in Additional file 5: Table S4A): 1) immune
stimulatory signaling; 2) immune effector activation,
including NK cell-mediated cytotoxicity, T cell, and B
cell signaling; and 3) inflammatory pathways activated in
immune-related diseases. The top KEGG pathways
enriched among the 809 genes down regulated in
GL261(B6) tumors are primarily involved in tumor cell
essential survival functions (Table 3B; Additional file 5:
Table S4A), consistent with the strong tumor regression
induced by CPA/6d treatment.
In LLC tumors, the 151 genes up regulated by CPA/6d
(Table 1) are most highly enriched in KEGG pathways
related to focal adhesion, ECM-receptor interaction and
complement and coagulation cascades (Additional file 5:
Table S4B), which include genes related to immune
stimulatory signaling. The 70 CPA-down regulated LLC
genes are enriched for cell adhesion molecules and
leukocyte transendothelial migration (Additional file 5:
Table S4B). The latter two pathways, which are up regu-
lated in GL261(B6) tumors (Table 3A), are critical for
tumor infiltration by immune cells [46]; their down
regulation in LLC tumors may contribute to LLC low
immune responsiveness.
The 663 genes up regulated in CPA/6d-treated B16F10
tumors (Table 1) are enriched for p53 signaling, which
may regulate tumor cell response to CPA at the level of
DNA damage response and immune response, as well as
10 other KEGG pathways related to immune stimulatory
signaling or immune-related diseases: lysosomes [47],
complement and coagulation cascades, systemic lupus
erythematosus, cytokine-cytokine receptor interactions,
Table 2 Unique UPRs induced by CPA in GL261(B6) compared to LLC and B16F10 tumors. Shown are the 47 UPRs unique to CPA-
treated GL261(B6) tumors identified in Additional file 4: Table S3G, classified into 4 categories based on their functions. Group 1 UPRs
are expected to contribute to the anti-tumor response, group 2 UPRs counter the anti-tumor response, and the actions of group 3
UPRs depend on cell context. Only two of the UPRs are associated with the glioma-specific lineage of GL261 tumors (group 4)
Category Reported function Predicted activation state Molecule type Upstream regulator
1. Facilitate tumor regression by
immune-mediated mechanisms or
by inhibiting tumor cell survival
Activate immune
responses
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Wu et al. BMC Cancer  (2016) 16:623 Page 8 of 17prion disease [48], JAK-STAT signaling, chemokine signal-
ing, antigen processing and presentation, cell adhesion
molecules, and ECM-receptor interaction (Additional
file 5: Table S4C). However, in contrast to GL261(B6)
tumors, immune effector activation pathways were not
enriched in the metronomic CPA responses in B16F10 tu-
mors, which may explain why activation of the above 10
pathways is not sufficient for a robust anti-tumor immune
response in B16F10 tumors. The set of 394 down regu-
lated B16F10 genes (Table 1) is enriched in tumor growth-
related pathways, such as cell cycle, DNA replication,
serine and threonine metabolism, one carbon pool by fol-
ate, steroid biosynthesis, terpenoid backbone biosynthesis,
and pyrimidine metabolism (Additional file 5: Table S4C),consistent with the moderate B16F10 tumor growth delay
induced by CPA treatment (Fig. 1). The down regulation
of serine and threonine metabolism may lead to a de-
crease in glutathione levels [49, 50] and thereby sensitize
B16F10 tumor cells to the cytotoxicity of CPA.
Gene pathways predictive of differential responsiveness
to CPA in untreated tumors
LLC, B16F10 and GL261 tumor cells all show substantial
intrinsic sensitivity to activated CPA cytotoxicity (Fig. 1a)
at concentrations well below those reached in tumor-
bearing mice given CPA/6d treatments [17]. Accordingly,
we hypothesize that their differential responsiveness to


















LLC, untreated LLC + CPA/6d
Fig. 2 Impact of CPA/6d treatment on LLC tumor microvessel density. Immunohistochemcal staining of blood vessel marker CD31 in LLC tumor
sections from untreated or CPA/6d-treated tumors, 6 days after the third CPA treatment. a, relative CD31 staining intensity, mean ± SE for n = 8
tumors/group; *p < 0.05 by two-tailed t-test. b, representative figure for each tumor group shown in (a)
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each tumor cell line with host stromal cells. To identify
genes and pathways active in untreated tumors that are
associated with, and may be predictive of, this differential
responsiveness to metronomic CPA treatment, we com-
pared the transcriptional profiles of untreated GL261 tu-
mors to those of untreated LLC and B16F10 tumors. We
identified 1348 genes showing significantly higher basal
expression and 438 genes showing significantly lower
basal expression in the responsive tumors than in both un-
responsive tumor models (Additional file 7: Tables S7A-B,
Additional file 2: Figure S7). Unexpectedly, the genes more
highly expressed in the responsive tumors were enriched
for immune-related signaling pathways, including immune
effector signaling, immune stimulatory signaling, and im-
mune disease (Additional file 8: Table S8A). The strongest
enrichment was for cell adhesion genes, many of which
are involved in antigen processing and presentation and
other immune responses. Only two of the enrichedpathways (axon guidance and prion diseases) were related
to the neuronal cell lineage of GL261 tumors. Thus, basal
immune activity is higher in the responsive tumors and
may positively impact responsiveness to CPA-induced
immunity.
Strikingly, 44 % of the 1348 genes with higher basal
expression in GL261(B6) tumors showed a significant
change in expression following CPA/6d treatment, a 3.5-
fold enrichment when compared to the 12.6 % response
rate for all genes (Additional file 7: Table S7C, legend).
Thus, the pathways dysregulated by CPA/6d are already
primed to be differentially expressed in untreated GL261
tumors. Immune activation-related pathways were sig-
nificantly enriched in the genes with higher basal expres-
sion that were up regulated by CPA (Additional file 8:
Table S8B), while glycine, serine and threonine metabol-
ism and focal adhesion were significantly enriched in the
CPA down regulated genes (Additional file 8: Table S8C).
The down regulation of glycine, serine and threonine
Table 3 KEGG pathways responded to CPA in GL261(B6) tumors
A. Top up regulated pathways
Gene Count % P-Value
Immuno-stimulatory signaling pathways mmu04060:Cytokine-cytokine receptor interaction 105 5.05 1.36E-30
mmu04142:Lysosome 50 2.41 4.61E-14
mmu04514:Cell adhesion molecules (CAMs) 55 2.65 5.33E-12
mmu04062:Chemokine signaling pathway 59 2.84 7.45E-11
mmu04630:Jak-STAT signaling pathway 50 2.41 1.51E-09
mmu04620:Toll-like receptor signaling pathway 38 1.83 1.71E-09
mmu04512:ECM-receptor interaction 34 1.64 2.09E-09
mmu04621:NOD-like receptor signaling pathway 27 1.30 2.96E-08
mmu04612:Antigen processing and presentation 32 1.54 4.18E-07
mmu04510:Focal adhesion 53 2.55 9.28E-07
mmu04210:Apoptosis 29 1.40 5.42E-06
mmu04610:Complement and coagulation cascades 25 1.20 2.82E-05
mmu05340:Primary immunodeficiency 16 0.77 2.88E-05
mmu04670:Leukocyte transendothelial migration 33 1.59 7.23E-05
Immune effector activation pathway mmu04650:Natural killer cell mediated cytotoxicity 56 2.69 7.15E-18
mmu04660:T cell receptor signaling pathway 39 1.88 1.13E-07
mmu04662:B cell receptor signaling pathway 30 1.44 2.18E-07
Pathways in immune related disease mmu04640:Hematopoietic cell lineage 45 2.17 1.28E-17
mmu05332:Graft-versus-host disease 31 1.49 3.57E-12
mmu04940:Type I diabetes mellitus 28 1.35 9.06E-09
mmu05330:Allograft rejection 26 1.25 2.82E-08
mmu05416:Viral myocarditis 31 1.49 3.05E-06
mmu04672:Intestinal immune network for IgA production 21 1.01 1.16E-05
mmu05320:Autoimmune thyroid disease 25 1.20 1.30E-05
mmu05322:Systemic lupus erythematosus 29 1.40 1.65E-04
B. Top down regulated pathways
Tumor cell essential function pathways mmu00100: Steroid biosynthesis 10 1.28 1.45E-09
mmu00900: Terpenoid backbone biosynthesis 8 1.02 1.80E-07
mmu03030: DNA replication 10 1.28 2.41E-06
mmu00240: Pyrimidine metabolism 14 1.79 2.95E-05
mmu04110: Cell cycle 16 2.04 4.15E-05
KEGG pathways enriched at p < 0.0001 in the sets of genes up regulated (A) or down regulated (B) by CPA in GL261(B6) tumors (Additional file 1: Table S1A). The
complete set of KEGG pathways identified is shown in Additional file 5: Table S4A. Related KEGG pathways were grouped into categories, as shown. Count, number of
input genes associated with the particular pathway; %, percentage of input genes associated with the particular term as a percent of total input genes. P Value,
modified Fisher Exact P-Value output from David analysis
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GL261 tumor cells and sensitize them to CPA cytotoxicity
[49]. Genes related to glial cells and neuron establishment
were also significantly enriched in the CPA down regu-
lated gene set (Additional file 8: Table S8D).
The 438 genes showing significantly lower basal ex-
pression in responsive tumors compared to both unre-
sponsive tumor models (Additional file 7: Table S7B) are
most highly enriched for glutathione metabolism and
other metabolic pathways (Additional file 8: Table S8E).These pathways include glutathione S-transferases GSTM1
and GSTP1, which are associated with resistance to CPA
[51, 52]. Further, lower basal GL261(B6) expression was
seen for glycolysis/gluconeogenesis and for the lysosome
pathway, which degrades/recycles macromolecules via
endocytosis, phagocytosis and autophagy, suggesting the
responsive tumors have a low metabolic rate [53]. 147 of
the 438 genes showing lower basal expression in
GL261(B6) tumors were up regulated by CPA/6d treat-
ment; only one gene was down regulated (Additional
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some pathway, blood vessel morphogenesis, pleckstrin
homology-type, glycoprotein, and endosome/cytoplasmic
membrane-bounded vesicle (Additional file 8: Table S8F).
Up regulation of the endosome-lysosome pathway may
enhance immunogenic tumor cell death by increasing di-
gestion, processing and presentation of tumor antigens
[54]. Up regulation of blood vessel morphogenesis may in-
crease tumor uptake of active CPA metabolites and im-
mune cell recruitment into tumors [55–57].
Negative regulators of immune response
CPA alteration of immune suppressive factors in the
tumor microenvironment could contribute to differences
in chemotherapy-induced immune responses between
tumor models. To determine whether CPA depletes such
immune suppressive factors, we compared the full set of
CPA-responsive genes in each tumor model with a set of
124 negative regulators of immune response (Additional
file 6: Table S5B; Additional file 8: Figure S8). Surprisingly,
in GL261(B6) tumors, only one of the 124 genes was
down regulated by CPA/6d treatment (CR2, FC = −2.1),
while 57 genes were up regulated (Additional file 6:
Table S5C). Further, CPA up regulated only 4 of the 124
negative regulators in LLC tumors and 17 in B16F10
tumors (Additional file 6: Table S5D, Additional file 6:
Table S5E). One negative regulator of immune response
was down regulated by CPA treatment in LLC tumors
(Hmox1, FC = −2.2) and no negative regulators of immune
response were down regulated in B16F10 tumors. No
negative regulators of immune response were uniquely up
regulated by CPA (>2-fold difference) in the two unre-
sponsive tumor models as compared to GL261(B6) tu-
mors. Consistently, 48 negative regulators of immune
response were expressed at a higher level and none was
expressed at a lower level in CPA-treated GL261(B6)
tumors than in CPA-treated LLC and B16F10 tumors
(Additional file 6: Table S5F). Further, we identified 20
negative immune regulators expressed at a significantly
higher basal level in untreated GL261 tumors than in
untreated LLC and B16F10 tumors (Additional file 6:
Table S5G), whereas only one negative regulator,
HMOX1, showed significantly lower basal expression in
GL261 tumors. Thus, the lack of robust immune responses
in CPA-treated LLC and B16F10 tumors cannot be attrib-
uted to a more immune suppressive microenvironment, ei-
ther basally or following CPA treatment. Further, the
strong immune response in CPA-treated GL261(B6) tu-
mors apparently occurs in spite of elevated basal immunity.
Differential GL261 tumor responses in scid vs. immune
competent B6 mouse host
We sought to identify genes and signaling pathways that
underlie the more complete and durable anti-tumorresponses that CPA/6d induces in GL261 tumors im-
planted in B6 mice [20] as compared to adaptive im-
mune system deficient scid mice [18]. Large numbers of
genes showed common responses to metronomic CPA
in both mouse models (Additional file 9: Table S10A, B,
Additional file 2: Figure S1B), with enrichment for
KEGG pathways similar to those described above for the
B6 model alone (Additional file 10: Table S11A-C).
Many fewer genes (Additional file 9: Table S10C-F;
Additional file 2: Figure S6) and KEGG pathways
(Additional file 10: Table S11D, E) showed significant
differential responses between B6 and scid mouse hosts,
consistent with the overall similarity of innate immune
and anti-tumor responses seen in CPA/6d-treated
GL261(scid) and GL261(B6) tumors [16, 18, 20].
The top three KEGG pathways enriched in the set of 130
genes up regulated by CPA/6d specifically in GL261(B6)
compared to GL261(scid) tumors are immune-related:
cytokine-cytokine receptor interactions, T cell receptor
signaling, and hematopoietic cell lineage, which is mostly
comprised of T cell lineage markers (Additional file 10:
Table S11D). Primary immunodeficiency was specifically
inhibited (p = 0.0041), reflecting the up regulation of Cd8
(marker for cytotoxic T cells), Cd3δ, Cd3ε (required for
differentiation of pro-T cells into pre-T cells) and Lck (re-
quired for Cd4+Cd8+ T cell differentiation into Cd8+ T
cells) [58]. This is consistent with a strong Cd8+ T cell dif-
ferentiation program in CPA-treated GL261(B6) tumors.
Cell adhesion and antigen processing and presentation
were also specifically up regulated in GL261(B6) com-
pared to GL261(scid) tumors, consistent with the activa-
tion and contribution of Cd8+ T cells to tumor regression
in regressing GL261(B6) tumors [20]. The top KEGG
pathway enriched in genes specifically induced by CPA/6d
in GL261(scid) tumors (Additional file 10: Table S11E),
calcium signaling, may relate to the hyperactive innate im-
mune system of scid mice [59].
Five UPRs showed a response to CPA treatment
unique to either B6 or scid mice (Additional file 4:
Table S3J, K). No inhibited UPRs were unique to either
mouse model. Three activated UPRs associated with
immune activation were unique to CPA/6d-treated
GL261(B6) tumors: EIF2AK2 [26], IFNL1 [60] and MAVS
[61], while the two activated UPRs specific to GL261(scid)
tumor responses, DMD [62] and SPARC [34–36], have
glial cell-related functions:.
Gene responses associated with 6-day vs. 9-day
metronomic CPA schedules
The metronomic CPA treatment schedule can have a
major impact on the extent of immune cell infiltration
into treated tumors and the overall effectiveness of the
anti-tumor response [17, 18]. Significant NK cell recruit-
ment and major tumor regression are achieved when
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6 day (CPA/6d) or a 9 day repeating schedule (CPA/9d);
however, the NK cell response is transient on the CPA/
9d schedule and is followed by early tumor growth re-
bound, whereas NK cell recruitment and tumor growth
delay are both prolonged on the CPA/6d schedule [18].
We used these models to identify early molecular signal-
ing events associated with these schedule-dependent NK
cell and tumor regression responses by investigating
gene expression changes 6 days after two CPA/6d or two
CPA/9d treatment cycles, at which time major tumor re-
gression is evident on both schedules [18].
Large numbers of genes were responsive to both CPA
treatment schedules (Additional file 1: Table S1D-S1F),
with many genes regulated in common (Additional file 1:
Table S1F; Additional file 2: Figure S2). Many fewer genes
showed differential regulation between the CPA/6d and
CPA/9d schedules (Additional file 11: Table S12A,
Additional file 2: Figure S10A). To identify genes specific-
ally dysregulated by each CPA schedule, we relaxed the
stringency filter to a >1.33-fold difference in response be-
tween schedules, while keeping the significance filter for
genes under consideration unchanged at |FC| > 2 and p <
0.001 (Additional file 2: Figure S10B, Additional file 11:
Table S12B). The set of 54 CPA/6d schedule-specific up
regulated genes was enriched for cytokine-cytokine recep-
tor interactions and other immune-related pathways
(Additional file 12: Table S13A, B), suggesting that the
CPA/6d schedule activates a more extensive immune re-
sponse. The set of 172 genes preferentially up regulated
on the CPA/9d schedule was enriched for histidine metab-
olism (Additional file 12: Table S13C) and for a C-type
lectin cluster (Additional file 12: Table S13D). This cluster
includes 3 inhibitory lectin receptors expressed on mye-
loid and/or NK cells (CLEC1A [63], KLRA1 [64], KLRA3
[65]), KLRA10, which is closely related in structure to in-
hibitory Ly49C receptors [66], and MGL2, a marker for
pro-tumor macrophages [67]. These genes may contribute
to the inability of the CPA/9d schedule to sustain an anti-
tumor immune response.
Applying a |FC| > 1.5 and p < 0.001 gene expression fil-
ter to compare responses in CPA/9d-treated tumors with
CPA/6d-treated tumors, we identified 151 genes expressed
at a higher level and 10 genes expressed at a lower level in
CPA/9d-treated tumors than in CPA/6d-treated GL261
(scid) tumors (Additional file 11: Table S12C; Additional
file 2: Figure S10C). The top enriched pathways in the 151
gene set, drug/xenobiotic metabolism and glutathione
metabolism (Additional file 12: Table S13E), relate to
chemotherapy resistance. Another enriched pathway,
hematopoietic cell lineage, is associated with platelet,
erythrocyte, neutrophil, and macrophage differentiation
(Additional file 2: Figure S11), which may be linked to tis-
sue repair and resistance to chemotherapy. Glycolysis/gluconeogenesis, which is also enriched among these 151
genes, might reflect increased tumor cell proliferation.
The 10 genes showing lower expression in CPA/9d-
treated tumors includes CXCL11, which suggests reduced
anti-tumor IFN signaling [68].
Finally, we considered individual genes with an expres-
sion intensity (normalized RNA-seq read number) > 50 in
either untreated or CPA-treated tumors, among the gene
changes showing >2-fold differential response to each
CPA schedule. PER2, TM7SF4, RETNLA and 10 other
genes were thus identified as being uniquely up regulated
on the CPA/9d schedule; no genes were uniquely down
regulated by the CPA/9d schedule (Additional file 11:
Table S12D). PER2 is a potential negative regulator of
TLR9-mediated innate and adaptive immune responses
[69]. TM7SF4 is a negative regulator of dendritic cell ac-
tivity that can maintain immune self-tolerance [70], and
RETNLA is highly expressed in alternative activated (M2)
macrophages [71] and can stimulate proliferation of mes-
enchymal stem cells as well as angiogenesis [72]. Thus,
these genes may contribute to the impaired NK cell re-
sponse seen in CPA/9d-treated tumors. Further, XIST was
uniquely up regulated – more than 20-fold – and SMPD3
was uniquely down regulated by the CPA/6d schedule
(Additional file 11: Table S12D). XIST expression corre-
lates with ovarian cancer cell sensitivity to taxol and high
XIST levels are associated with late relapse [73]. SMPD3,
which is down regulated uniquely in CPA/6d-treated
GL261(scid) tumors, can promote angiogenesis within the
tumor microenvironment as well as metastasis by regulat-
ing exosomal microRNA secretion [74]. No negative regu-
lators of immune response were unique to either CPA
schedule.
Discussion
The immune anti-tumor action of CPA is highly
dependent on schedule, as seen in several glioma models,
where optimal immune-based regression is achieved using
a 6-day repeating metronomic schedule of drug treatment
(CPA/6d), but not when using more frequent [16, 17] or
less frequent scheduling [18]. This ability of CPA/6d treat-
ment to activate a strong, tumor regressing immune re-
sponse is highly dependent on the tumor model, as shown
by our studies of LLC Lewis lung carcinoma and B16F10
melanoma, which are intrinsically sensitive to activated
CPA in cell culture but do not exhibit the potent CPA-
inducible anti-tumor immune responses and robust re-
gression seen with GL261 gliomas in the same syngeneic
B6 mouse model. Global transcriptional profiling, by
RNA-seq, was employed to identify the gene, pathway and
upstream regulator (UPR) responses that underlie the dif-
ferential CPA immune responsiveness of GL261 (respon-
sive) versus LLC and B16F10 (unresponsive) tumors, and
to elucidate the impact of host immune status and
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these gene responses.
Molecular mechanisms associated with differential tumor
responsiveness to metronomic CPA
Immune stimulatory and immune effector KEGG path-
ways dominated the top up regulated gene responses to
metronomic CPA treatment (CPA/6d schedule) in GL261,
but not LLC or B16F10 tumors, while tumor cell survival
pathways typified the down regulated gene responses.
Consistently, a majority of immunogenic cell death path-
way genes with good prognostic impact [75] were induced
by CPA/6d treatment in GL261 tumors, but not in LLC or
B16F10 tumors. These include genes involved in TLR sig-
naling, the purinergic receptor-Inflammasome-interleukin1β
axis, innate immune effectors, T cell infiltration, and T cell
effectors. Examination of the UPRs linked to the gene re-
sponses induced by CPA in each tumor model revealed
that many UPRs uniquely associated with CPA/6d-treated
GL261 tumors are factors that facilitate tumor regression
by immune mechanisms or inhibit tumor cell survival
(Table 2). Few unique UPRs were associated with B16F10
tumors, and even fewer UPRs with LLC tumors, which
showed the weakest anti-tumor response and the fewest
dysregulated genes (Table 1), despite their high intrinsic
sensitivity to CPA cytotoxicity. One UPR, the pro-
angiogenic factor VEGFA, was activated by CPA treat-
ment in GL261 tumors but was uniquely inhibited in LLC
tumors, as was validated by analysis of CPA effects on
LLC tumor microvessel density. This differential activa-
tion status of VEGFA between GL261 and LLC tumors
correlates with the level of immune cell marker gene infil-
tration in each tumor model and is consistent with the re-
quirement for VEGFA/VEGFR2 signaling for CPA to
activate immune cell recruitment in responding gliomas
[16, 19]. Both KEGG pathways down regulated in LLC tu-
mors, cell adhesion and leukocyte transendothelial migra-
tion, are critical for immune cell recruitment into the
tumor compartment. Presumably, the VEGFA inhibition/
anti-angiogenesis seen in CPA/6d-treated LLC tumors
combined with the down regulation of cell adhesion mole-
cules and leukocyte transendothelial migration suppresses
an important route of immune cell infiltration.
CPA/6d treatment of B16F10 tumors induced more
prolonged growth delay and many more gene responses,
including immune-related gene responses, than in LLC
tumors (Table 1). The CPA/6d-treated B16F10 tumors
shared 59 UPRs in common with GL261 tumors, includ-
ing several UPRs important for immune cell responses,
notably IFNAR1, IFNB1, IFNG, and IRF7. However,
B16F10 tumor gene responses were not enriched for any
of the immune effector KEGG pathways found in GL261
tumors, such as NK cell cytotoxicity and T cell receptor
signaling, even though other immune activation pathwayswere enriched, including cytokine-cytokine receptor
interaction, chemokine signaling pathway, and antigen
processing and presentation. Direct comparison of the
CPA-induced gene responses between responsive (GL261)
and unresponsive (LLC and B16F10) tumor models
(Additional file 13: Table S6) suggested that activation of
T cell receptor signaling, inhibition of primary immuno-
deficiency, and leukocyte transendothelial migration are
more extensive (greater fraction of pathway genes, lower
p-value) in the responsive tumors (Additional file 13:
Table S6F). CPA induced only four chemokines in B16F10
tumors, CCL5, CCL6, CCL7 and CCL9, all related to
monocyte and lymphocyte recruitment [76], while in LLC
tumors only one chemokine was induced, CCL11, which
recruits eosinophils [77]. In contrast, 30 different chemo-
kine and chemokine receptor genes, many important for
NK cell and T cell recruitment, were up regulated in CPA-
treated GL261 tumors (Additional file 1: Table S1A).
Based on these findings, adoptive transfer of activated
lymphocytes and/or delivery of chemokines that increase
NK cell or T cell tumor infiltration might synergistically
enhance responses to CPA treatment of B16F10 tumors.
High basal immune infiltration in GL261 tumors
As not all tumors intrinsically sensitive to CPA cytotox-
icity mount a strong immune response to metronomic
CPA, there is a need for markers to phenotype individual
tumors and select patients for CPA-based immunogenic
chemotherapy. Markers of immunogenic tumor cell
death alone are not likely to be sufficient, insofar as
HMGB1 release occurs in CPA-treated B16F10 tumors
[13], which we found are largely immune unresponsive
to CPA/6d treatment. Indeed, basal levels of expression
were similar or higher in the unresponsive tumors (LLC,
B16F10) compared to the responsive (GL261) tumors for
genes associated with immunogenic cell death danger
signal formation (CALR, HMGB1, HSP90AA1) and im-
munogenic cell death execution (ATG5, BAX, CASP8,
PDIA3, PIK3CA) (c.f. [75]). Further, immunogenic cell
death pathway danger signal degradation factors (ENTPD1,
NT5E) were the same or lower in the unresponsive tu-
mors. We also found, however, that basal expression of
many downstream immune stimulatory and immune-
effector genes, including genes associated with T cell
infiltration, is higher in the responsive compared to unre-
sponsive tumor models (Additional file 8: Table S8A). The
latter finding is consistent with the low level of MHC I ex-
pression reported in untreated LLC and B16F10 (i.e., un-
responsive) tumors in B6 mice [78], and suggests that
basal tumor immunogenicity may be predictive of a CPA/
6d-inducible immune response, in accordance with the
correlation between tumor immunogenicity and efficacy
of immunotherapy [78]. Of note, GL261 tumors are con-
sidered moderately immunogenic [79]. Interestingly, genes
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significantly enriched for CPA-responsive genes, suggest-
ing that CPA/6d treatment activates pathway(s) that are
already primed to be differentially expressed between re-
sponsive and unresponsive tumors. Basal gene expression
profiles may thus be useful in identifying tumors, and
perhaps patients, more likely to show effective immune
responsiveness to metronomic CPA. Studies in additional
tumor models, including gliomas with lower immunogen-
icity than GL261, are needed to confirm and extend these
findings and to exclude confounding factors such as
differences in mutation status and tumor histology. Histo-
logical differences between the responsive (glioma) and
unresponsive (lung carcinoma, melanoma) tumors exam-
ined are probably not a major factor in their differential
CPA immune responsiveness, as indicated by the rather
small number of neuronal-related KEGG pathways and
UPRs linked to the GL261-specific gene responses
(Additional file 8: Table S8A, Table 2).
Negative regulators of immune response
An immune suppressive tumor microenvironment may
dampen the efficacy of chemotherapy [80] and could be
a factor in the immune unresponsiveness of LLC and
B16F10 tumors. Three KEGG pathways with immune
suppressive potential were enriched in the gene set
expressed at a lower level in CPA-treated GL261 than
LLC and B16F10 tumors: steroid biosynthesis, which can
inhibit T cell development [81]; butanoate metabolism,
which can induce T cell apoptosis [82]; and tryptophan
metabolism, which can induce regulatory T cell prolifer-
ation [83] (Additional file 14: Table S9C), suggesting the
unresponsive tumors have a more highly immune sup-
pressive environment. However, many negative regula-
tors of immune response actually showed higher basal
expression in GL261 tumors, and/or were more com-
monly up regulated by CPA treatment in GL261 com-
pared to LLC and B16F10 tumors. This latter finding is
consistent with a feedback response leading to up
regulation of immunosuppressive T regulatory cells in
CPA-treated GL261 tumors [20, 84]. This effect is mini-
mized by giving CPA on a 6 day schedule [20], and may
be a factor driving the need for repeated CPA treatment
to maximize anti-tumor immune activity.
Impact of scid immunodeficiency
CPA/6d treatment of GL261 tumors implanted in adaptive
immune deficient scid mice induces major regression, but
is sometimes followed by late tumor growth rebound [18],
whereas in the fully immune competent B6 mouse model,
GL261 tumors are eradicated by a Cd8 T cell-dependent
mechanism with acquisition of long term immunity [20].
A subset of cytokine-cytokine receptor interaction, T cell
receptor signaling and several other immune-relatedKEGG pathway genes were unique to the GL261(B6)
tumor model as compared to the GL261(scid) model,
consistent with the importance of T cell receptor signaling
and cytokine-cytokine receptor interaction for the more
complete and long-lasting anti-tumor responses in
GL261(B6) tumors [20]. Further, three activated UPRs
associated with immune activation were unique to CPA/
6d-treated GL261(B6) tumors: EIF2AK2 is an intracellular
danger-sensing molecule important for inflammasome
activation and HMGB1 release [26]; IFNL1 can mediate
inflammatory responses in epithelial cells [60, 85]; and
MAVS is required for activation of NFkB and interferon
induction in response to viral infection [61]. The two
activated UPRs specific to GL261(scid) tumor responses
have glial cell-related functions: DMD may relate to glial
cell differentiation [62]; and SPARC can inhibit brain
tumor cell growth but also promotes invasion by increas-
ing binding of extracellular matrix proteins [34–36].
Extending CPA drug-free break from 6 to 9 days
We investigated gene responses in GL261(scid) tumors
treated with CPA on a 9 day repeating schedule (CPA/
9d), which initially induces tumor regression nearly as
effectively as CPA/6d treatment, but leads to a striking
rebound in tumor growth after treatment day ~24,
despite ongoing CPA treatment [18]. We found only a
small number of significant gene response differences
between the two CPA schedules, consistent with the very
similar overall tumor regression status of these two
tumor models at the time of tumor sampling after two
CPA treatment cycles. Genes specifically up regulated on
the CPA/6d schedule were enriched in cytokine-cytokine
receptor and other immune-related pathways, consistent
with the more sustained NK cell response in CPA/6d-
treated GL261(scid) tumors [18], while the CPA/9d
schedule preferentially up regulated a C-type lectin gene
cluster that includes several inhibitory lectin receptors
expressed on myeloid and/or NK cells (CLEC1A [63],
KLRA1 [64], and KLRA3 [65]). Other top pathways
preferentially enriched in CPA/9d-treated tumors in-
clude drug metabolism and glutathione metabolism,
which can confer chemotherapy resistance, suggesting
that the longer drug-free breaks on the CPA/9d schedule
facilitate selection of drug resistant tumor cells.
Conclusion
We identified several factors that are associated with,
and may contribute to the strong immune responsive-
ness of GL261 tumors to a 6 day repeating metronomic
schedule of CPA treatment; these include elevated basal
levels and higher CPA-induced levels of many immune
factors, enhanced blood vessel morphogenesis and
leukocyte transendothelial migration, and reduced basal
expression of drug metabolism genes compared to LLC
Wu et al. BMC Cancer  (2016) 16:623 Page 15 of 17and/or B16F10 tumors. Further studies, including genetic
ablation or pharmacological inhibition of key factors linked
to immune responsiveness, are required to establish causal
roles for these factors. Furthermore, analysis of isolated
tumor cell and immune cell populations may help elucidate
the cellular origin of these immune response regulators.
These factors likely work in concert to increase immunogenic
responses to metronomic CPA scheduling, and when taken
together, may help identify individual tumors most likely to
be responsive to immunogenic chemotherapy. This approach
is complementary to ongoing efforts to characterize tumors
by an immunoscore that integrates immune cell type, density,
location, and functional state and predicts cancer patient
responsiveness to therapy [86].Additional files
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